Eptifibatide

Comparative studies

In a systematic review of comparisons of eptifibatide (n = 2812) and abciximab (n = 729), there were no differences in the incidences of in-hospital death (4.1% with abciximab versus 3.5% with eptifibatide), recurrent myocardial infarction (0.8% versus 1.2%), or strokes/transient ischemic attacks (0.7% versus 0.6%) [ ]. There was no difference in the need for blood transfusion (12.4% versus 11.7%), but there was a higher incidence of gastrointestinal bleeding with abciximab (4.8% versus 2.8%).